Reacciones adversas cutáneas severas a medicamentos: estado del conocimiento
Resumen
Las reacciones adversas a medicamentos afectan de manera global entre el 10% y el 20% de los pacientes hospitalizados y el 7% de los pacientes ambulatorios. Aproximadamente, uno de cada mil pacientes hospitalizados sufren reacciones adversas que amenazan la vida. Las reacciones adversas a medicamentos, denominadas como reacciones alérgicas (inmunológicas), se pueden agrupar según la clasificación de Gell y Coombs en: tipo I (mediada por IgE), tipo II (citotóxica), tipo III (por inmunocomplejos) y tipo IV (hipersensibilidad retardada o celular). Actualmente, las reacciones tipo IV se subclasifican según la célula efectora involucrada y sus correspondientes citoquinas. Estos subgrupos se definen como: tipo IVa (con activación del perfil Th1, los macrófagos como células efectoras y liberación de INF-γ y TNF-α), tipo IVb (con activación del perfil Th2, los eosinófilos como células efectoras y liberación de citoquinas como la IL-5, la IL-4 y la IL-13), tipo IVc (con los linfocitos T citotóxicos como células efectoras y liberación de granzimas B y perforinas) y tipo IVd (con los neutrófilos como células efectoras y liberación de CXCL8 y factor estimulante de colonias de granulocitos y macrófagos). La presente revisión se centra en la epidemiología, etiología, fisiopatología y manifestaciones clínicas de las reacciones adversas cutáneas severas a medicamentos como el síndrome de Stevens Johnson, la necrólisis epidérmica tóxica, el síndrome DRESS y la pustulosis exantemática generalizada aguda (PEGA); además de un abordaje terapéutico en cada una de estas enfermedades.
Descargas
Referencias bibliográficas
Hoetzenecker W, Nageli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol 2016; 38: 75-86.
https://doi.org/10.1007/s00281-015-0540-2
Marzano AV, Borghi A, Cugno M. Adverse drug reactions and organ damage: The skin. Eur J Intern Med 2016; 28: 17-24.
https://doi.org/10.1016/j.ejim.2015.11.017
Martin T, Li H. Severe cutaneous adverse drug reactions: a review on epidemiology, etiology, clinical manifestation and pathogenesis. Chin Med J (Engl) 2008; 121: 756-761.
https://doi.org/10.1097/00029330-200804020-00019
Wooten JM. Adverse drug reactions: Part I. South Med J 2010; 103: 1025-1028; quiz 1029.
https://doi.org/10.1097/SMJ.0b013e3181f0c866
Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94: 419-436; quiz 436-418, 456.
https://doi.org/10.1016/S1081-1206(10)61112-X
Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44.
https://doi.org/10.1038/sj.jid.5701033
Serrano-Reyes C, Escobar-Valencia MF, Cardona-Villa R. Reacciones severas de hipersensibilidad a medicamentos. En: Cardona-Villa R, Serrano-Reyes C, eds. Alergia: abordaje clínico, diagnóstico y tratamiento. Bogotá D.C., Colombia: Editorial Médica Panamericana; 2010: 572-580.
Pichler WJ. Immune mechanism of drug hypersensitivity. Immunol Allergy Clin North Am 2004; 24: 373-397, v-vi.
https://doi.org/10.1016/j.iac.2004.03.012
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69: 173 e171-113; quiz 185-176.
https://doi.org/10.1016/j.jaad.2013.05.003
Browne BJ, Edwards B, Rogers RL. Dermatologic emergencies. Prim Care 2006; 33: 685-695, vi.
https://doi.org/10.1016/j.pop.2006.06.002
Harr T, French LE. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. Med Clin North Am 2010; 94: 727-742, x.
https://doi.org/10.1016/j.mcna.2010.04.004
Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol 2016; 174: 1194-1227.
https://doi.org/10.1111/bjd.14530
Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011; 7: 803-813; quiz 814-805.
https://doi.org/10.1586/eci.11.66
Patterson R, Miller M, Kaplan M, Doan T, Brown J, Detjen P, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994; 73: 27-34.
Patterson R, Grammer LC, Greenberger PA, Lawrence ID, Zeiss CR, Detjen PF, et al. Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allergy Proc 1992; 13: 89-95.
https://doi.org/10.2500/108854192778878926
Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J Invest Dermatol 2016; 136: 1387-1397.
https://doi.org/10.1016/j.jid.2016.03.023
Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
https://doi.org/10.1001/archderm.1993.01680220104023
Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol 2012; 66: 995-1003.
https://doi.org/10.1016/j.jaad.2011.09.029
Schalock PC, Dinulos JG. Mycoplasma pneumoniae-induced Stevens-Johnson syndrome without skin lesions: fact or fiction? J Am Acad Dermatol 2005; 52: 312-315.
https://doi.org/10.1016/j.jaad.2004.07.044
Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med 2011; 39: 1521-1532.
https://doi.org/10.1097/CCM.0b013e31821201ed
Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
https://doi.org/10.1038/428486a
Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol 2013; 25: 81-89.
https://doi.org/10.1016/j.coi.2012.10.002
Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134-4139.
https://doi.org/10.1073/pnas.0409500102
Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617-1622.
https://doi.org/10.2217/14622416.9.11.1617
Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
https://doi.org/10.1097/FPC.0b013e3282f3ef9c
Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704-709.
https://doi.org/10.1097/FPC.0b013e328330a3b8
Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013; 54: 1307-1314.
https://doi.org/10.1111/epi.12217
Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-1215.
https://doi.org/10.1016/j.jaci.2004.07.047
Tohyama M, Hashimoto K. Immunological mechanisms of epidermal damage in toxic epidermal necrolysis. Curr Opin Allergy Clin Immunol 2012; 12: 376-382.
https://doi.org/10.1097/ACI.0b013e328355b865
Pierard GE, Paquet P. Facing up to toxic epidermal necrolysis. Expert Opin Pharmacother 2010; 11: 2443-2446.
https://doi.org/10.1517/14656566.2010.512915
Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343-1350.
https://doi.org/10.1038/nm.1884
Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182: 8071-8079.
https://doi.org/10.4049/jimmunol.0804002
Abe R. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatol 2015; 42: 42-48.
https://doi.org/10.1111/1346-8138.12674
Wheatley LM, Plaut M, Schwaninger JM, Banerji A, Castells M, Finkelman FD, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. J Allergy Clin Immunol 2015; 136: 262-271 e262.
https://doi.org/10.1016/j.jaci.2015.05.027
Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006; 55: 27-33.
https://doi.org/10.2332/allergolint.55.27
Morales ME, Purdue GF, Verity SM, Arnoldo BD, Blomquist PH. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. Am J Ophthalmol 2010; 150: 505-510 e501.
https://doi.org/10.1016/j.ajo.2010.04.026
Lim VM, Do A, Berger TG, Nguyen AH, DeWeese J, Malone JD, et al. A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness. Burns 2016; 42: 836-843.
https://doi.org/10.1016/j.burns.2016.01.014
Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dume L, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35: 234-236.
https://doi.org/10.1111/j.1600-0536.1996.tb02364.x
Hassoun-Kheir N, Bergman R, Weltfriend S. The use of patch tests in the diagnosis of delayed hypersensitivity drug eruptions. Int J Dermatol 2016; 55: 1219-1224.
https://doi.org/10.1111/ijd.13306
Zawodniak A, Lochmatter P, Yerly D, Kawabata T, Lerch M, Yawalkar N, et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 2010; 65: 376-384.
https://doi.org/10.1111/j.1398-9995.2009.02180.x
Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2016; 71: 1103-1134.
https://doi.org/10.1111/all.12886
Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62: 1439-1444.
https://doi.org/10.1111/j.1398-9995.2007.01553.x
Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-327.
https://doi.org/10.1001/archderm.136.3.323
Mehregan D, Van Vreede A, Goralewski M. Toxic epidermal necrolysis treatment and outcomes: a retrospective analysis of 10 patients treated with intravenous immunoglobulin. Int J Dermatol 2016; 55: e356-360.
https://doi.org/10.1111/ijd.13156
Gaitanis G, Spyridonos P, Patmanidis K, Koulouras V, Nakos G, Tzaphlidou M, et al. Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin. Dermatology 2012; 224: 134-139.
https://doi.org/10.1159/000338202
Zarate-Correa LC, Carrillo-Gomez DC, Ramirez-Escobar AF, Serrano-Reyes C. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol 2013; 23: 61-63.
Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153.
https://doi.org/10.1046/j.1523-1747.2000.00061.x
Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol 2011; 36: 6-11.
https://doi.org/10.1111/j.1365-2230.2010.03967.x
Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250-257.
https://doi.org/10.1016/S1085-5629(96)80038-1
Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950; 242: 897-898.
https://doi.org/10.1056/NEJM195006082422304
Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am 2009; 29: 481-501.
https://doi.org/10.1016/j.iac.2009.04.007
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124: 588-597.
https://doi.org/10.1016/j.amjmed.2011.01.017
Spriet S, Banks TA. Drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Proc 2015; 36: 501-505.
https://doi.org/10.2500/aap.2015.36.3903
Descamps V, Ben Said B, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, et al. [Management of drug reaction with eosinophilia and systemic symptoms (DRESS)]. Ann Dermatol Venereol 2010; 137: 703-708.
https://doi.org/10.1016/j.annder.2010.04.024
Skowron F, Bensaid B, Balme B, Depaepe L, Kanitakis J, Nosbaum A, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. J Eur Acad Dermatol Venereol 2015; 29: 2199-2205.
https://doi.org/10.1111/jdv.13212
Ganeva M, Gancheva T, Lazarova R, Troeva J, Baldaranov I, Vassilev I, et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 2008; 47: 853-860.
https://doi.org/10.1111/j.1365-4632.2008.03637.x
Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7: 813-818.
https://doi.org/10.2217/14622416.7.6.813
Hsiao YH, Hui RC, Wu T, Chang WC, Hsih MS, Yang CH, et al. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. J Dermatol Sci 2014; 73: 101-109.
https://doi.org/10.1016/j.jdermsci.2013.10.003
Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014; 14: 281-288.
https://doi.org/10.1038/tpj.2013.40
Sousa-Pinto B, Pinto-Ramos J, Correia C, Goncalves-Costa G, Gomes L, Gil-Mata S, et al. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01. J Allergy Clin Immunol 2015; 136: 1092-1094 e1093.
https://doi.org/10.1016/j.jaci.2015.03.019
Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301-304.
Tohyama M, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima K, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007; 157: 934-940.
https://doi.org/10.1111/j.1365-2133.2007.08167.x
Seishima M, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 2006; 155: 344-349.
https://doi.org/10.1111/j.1365-2133.2006.07332.x
Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007; 27: 1425-1439.
https://doi.org/10.1592/phco.27.10.1425
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 2013; 68: 693 e691-614; quiz 706-698.
https://doi.org/10.1016/j.jaad.2013.01.033
Criado PR, Criado RF, Avancini JM, Santi CG. Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts. An Bras Dermatol 2012; 87: 435-449.
https://doi.org/10.1590/S0365-05962012000300013
Hirahara K, Kano Y, Mitsuyama Y, Takahashi R, Kimishima M, Shiohara T. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions. Clin Exp Dermatol 2010; 35: 863-868.
https://doi.org/10.1111/j.1365-2230.2010.03820.x
Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 1998; 139: 1026-1032.
https://doi.org/10.1046/j.1365-2133.1998.02559.x
Sultan SJ, Sameem F, Ashraf M. Drug reaction with eosinophilia and systemic symptoms: manifestations, treatment, and outcome in 17 patients. Int J Dermatol 2015; 54: 537-542.
https://doi.org/10.1111/ijd.12331
Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, Wechsler J, de Feraudy S, Duong TA, et al. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol 2015; 173: 50-58.
https://doi.org/10.1111/bjd.13683
Ghislain PD, Bodarwe AD, Vanderdonckt O, Tennstedt D, Marot L, Lachapelle JM. Drug-induced eosinophilia and multisystemic failure with positive patch-test reaction to spironolactone: DRESS syndrome. Acta Derm Venereol 2004; 84: 65-68.
https://doi.org/10.1080/00015550310005915
Charfi O, Lakhoua G, Sahnoun R, Badri T, Daghfous R, El Aidli S, et al. DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test. Therapie 2015; 70: 547-549.
https://doi.org/10.2515/therapie/2015046
Mahajan VK, Handa S. Patch testing in cutaneous adverse drug reactions: methodology, interpretation, and clinical relevance. Indian J Dermatol Venereol Leprol 2013; 79: 836-841.
https://doi.org/10.4103/0378-6323.120751
Santiago F, Goncalo M, Vieira R, Coelho S, Figueiredo A. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis 2010; 62: 47-53.
https://doi.org/10.1111/j.1600-0536.2009.01659.x
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol 2013; 68: 709 e701-709; quiz 718-720.
https://doi.org/10.1016/j.jaad.2013.01.032
Lee HY, Chou D, Pang SM, Thirumoorthy T. Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore. Int J Dermatol 2010; 49: 507-512.
https://doi.org/10.1111/j.1365-4632.2010.04313.x
Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol 2010; 20: 425-433.
https://doi.org/10.1684/ejd.2010.0932
Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001; 28: 113-119.
https://doi.org/10.1034/j.1600-0560.2001.028003113.x
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol 2015; 73: 843-848.
https://doi.org/10.1016/j.jaad.2015.07.017
Mashiah J, Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol 2003; 139: 1181-1183.
https://doi.org/10.1001/archderm.139.9.1181
Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809-820.
